{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T08:01:30Z","timestamp":1781164890834,"version":"3.54.1"},"reference-count":29,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["brachyjournal.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Brachytherapy"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.brachy.2025.10.013","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T08:49:18Z","timestamp":1763628558000},"page":"235-240","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Feasibility of combining high-dose-rate prostate brachytherapy with dose intensification to the MRI dominant lesion followed by real-time adaptive MR-guided pelvic radiotherapy for high-risk prostate cancer"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4252-6855","authenticated-orcid":false,"given":"Gil\u2019ad N.","family":"Cohen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8732-968X","authenticated-orcid":false,"given":"Jason","family":"Gurewitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-8244-8646","authenticated-orcid":false,"given":"Jeffrey","family":"Cooney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhao","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry","family":"Adler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2160-8616","authenticated-orcid":false,"given":"David J.","family":"Byun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Zelefsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.brachy.2025.10.013_bib0001","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.radonc.2020.09.047","article-title":"Randomised trial of external-beam radiotherapy alone or with high-dose-rate brachytherapy for prostate cancer: mature 12-year results","volume":"154","author":"Hoskin","year":"2021","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.brachy.2025.10.013_bib0002","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.brachy.2022.05.002","article-title":"After ASCENDE-RT: biochemical and survival outcomes following combined external beam radiotherapy and low-dose-rate brachytherapy for high-risk and unfavourable intermediate-risk prostate cancer, a population-based analysis","volume":"21","author":"Oh","year":"2022","journal-title":"Brachytherapy"},{"key":"10.1016\/j.brachy.2025.10.013_bib0003","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.ijrobp.2024.02.064","article-title":"A randomized trial comparing quality of life after low-dose rate or high-dose rate prostate brachytherapy boost with pelvic external beam radiation therapy","volume":"120","author":"Crook","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2025.10.013_bib0004","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ijrobp.2024.12.018","article-title":"Pelvic regional control with 25 gy in 5 fractions in stereotactic radiation therapy for high-risk prostate cancer: pooled prospective outcomes from the SHARP Consortium","volume":"122","author":"Murthy","year":"2025","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2025.10.013_bib0005","article-title":"Comparison of four-year toxicities and local control of ultra-hypofractionated vs moderate-hypofractionated image guided prostate radiation with HDR brachytherapy boost: a phase I-II single institution trial","volume":"40","author":"Beaudry","year":"2023","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.brachy.2025.10.013_bib0006","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.brachy.2020.02.008","article-title":"A phase IB clinical trial of 15 Gy HDR brachytherapy followed by hypofractionated\/SBRT in the management of intermediate-risk prostate cancer","volume":"19","author":"Den","year":"2020","journal-title":"Brachytherapy"},{"key":"10.1016\/j.brachy.2025.10.013_bib0007","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.brachy.2021.08.006","article-title":"Early outcomes of high-dose-rate brachytherapy combined with ultra-hypofractionated radiation in higher-risk prostate cancer","volume":"20","author":"Gorovets","year":"2021","journal-title":"Brachytherapy"},{"issue":"S126","key":"10.1016\/j.brachy.2025.10.013_bib0008","article-title":"Focal MR-guided HDR brachytherapy boost combined with SBRT for localized prostate cancer","volume":"120","author":"Johnny","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2025.10.013_bib0009","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.radonc.2016.09.016","article-title":"A combined single high-dose rate brachytherapy boost with hypofractionated external beam radiotherapy results in a high rate of biochemical disease free survival in localised intermediate and high risk prostate cancer patients","volume":"121","author":"Joseph","year":"2016","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.brachy.2025.10.013_bib0010","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.radonc.2021.05.024","article-title":"Stereotactic pelvic radiotherapy with HDR boost for dose escalation in intermediate and high-risk prostate cancer (SPARE): efficacy, toxicity and quality of life","volume":"161","author":"Musunuru","year":"2021","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.brachy.2025.10.013_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2024.110568","article-title":"Stereotactic body radiotherapy with a focal boost to the intraprostatic tumor for intermediate and high risk prostate cancer: 5-year efficacy and toxicity in the hypo-FLAME trial","volume":"201","author":"Draulans","year":"2024","journal-title":"Radiotherap Oncol"},{"key":"10.1016\/j.brachy.2025.10.013_bib0012","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1200\/JCO.20.02873","article-title":"Focal boost to the intraprostatic tumor in external beam radiotherapy for patients with localized prostate cancer: results from the FLAME randomized phase III trial","volume":"39","author":"Kerkmeijer","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.brachy.2025.10.013_bib0013","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1001\/jamaoncol.2022.6558","article-title":"Magnetic resonance imaging-guided vs computed tomography-guided stereotactic body radiotherapy for prostate cancer: the MIRAGE randomized clinical trial","volume":"9","author":"Kishan","year":"2023","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.brachy.2025.10.013_bib0014","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1007\/s11547-025-02014-x","article-title":"First clinical application of Comprehensive Motion Management with 1.5T MR-linac on prostate cancer patients treated with radiotherapy: technical aspects and suggested workflow recommendations","volume":"130","author":"Nicosia","year":"2025","journal-title":"Radiol Med"},{"key":"10.1016\/j.brachy.2025.10.013_bib0015","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.brachy.2024.12.005","article-title":"HDR brachytherapy combined with external beam radiotherapy for unfavorable localized prostate cancer: a single center experience from inception to standard of care","volume":"24","author":"Yeung","year":"2025","journal-title":"Brachytherapy"},{"key":"10.1016\/j.brachy.2025.10.013_bib0016","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1016\/j.ijrobp.2004.02.055","article-title":"Inverse planning for HDR prostate brachytherapy used to boost dominant intraprostatic lesions defined by magnetic resonance spectroscopy imaging","volume":"59","author":"Pouliot","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2025.10.013_bib0017","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.brachy.2014.05.006","article-title":"Ultrasound-planned high-dose-rate prostate brachytherapy: dose painting to the dominant intraprostatic lesion","volume":"13","author":"Crook","year":"2014","journal-title":"Brachytherapy"},{"key":"10.1016\/j.brachy.2025.10.013_bib0018","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.brachy.2019.01.006","article-title":"Dose to the dominant intraprostatic lesion using HDR vs. LDR monotherapy: a Phase II randomized trial","volume":"18","author":"Tissaverasinghe","year":"2019","journal-title":"Brachytherapy"},{"key":"10.1016\/j.brachy.2025.10.013_bib0019","doi-asserted-by":"crossref","first-page":"357","DOI":"10.21037\/tau.2017.12.08","article-title":"High dose-rate brachytherapy in the treatment of prostate cancer","volume":"7","author":"Mendez","year":"2018","journal-title":"Transl Androl Urol"},{"key":"10.1016\/j.brachy.2025.10.013_bib0020","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/1748-717X-7-31","article-title":"Long-term biochemical results after high-dose-rate intensity modulated brachytherapy with external beam radiotherapy for high risk prostate cancer","volume":"7","author":"Prada","year":"2012","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.brachy.2025.10.013_bib0021","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.radonc.2007.05.019","article-title":"Patterns of toxicity following high-dose-rate brachytherapy boost for prostate cancer: mature prospective phase I\/II study results","volume":"84","author":"Duchesne","year":"2007","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.brachy.2025.10.013_bib0022","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.ijrobp.2004.08.014","article-title":"High-dose-rate intensity-modulated brachytherapy with external beam radiotherapy for prostate cancer: california endocurietherapy's 10-year results","volume":"61","author":"Demanes","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2025.10.013_bib0023","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.brachy.2012.05.003","article-title":"Clinical outcomes of high-dose-rate brachytherapy and external beam radiotherapy in the management of clinically localized prostate cancer","volume":"12","author":"Kotecha","year":"2013","journal-title":"Brachytherapy"},{"key":"10.1016\/j.brachy.2025.10.013_bib0024","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.radonc.2017.06.012","article-title":"High-dose-rate brachytherapy boost for prostate cancer treatment: different combinations of hypofractionated regimens and clinical outcomes","volume":"124","author":"Vigneault","year":"2017","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.brachy.2025.10.013_bib0025","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/bju.13659","article-title":"Long-term outcomes of high-dose-rate brachytherapy for intermediate- and high-risk prostate cancer with a median follow-up of 10 years","volume":"120","author":"Yaxley","year":"2017","journal-title":"BJU Int"},{"key":"10.1016\/j.brachy.2025.10.013_bib0026","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.ijrobp.2006.04.045","article-title":"High-dose irradiation for prostate cancer via a high-dose-rate brachytherapy boost: results of a phase I to II study","volume":"66","author":"Vargas","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2025.10.013_bib0027","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1097\/COC.0b013e3181b9cd2f","article-title":"High-dose-rate prostate brachytherapy: an excellent accelerated-hypofractionated treatment for favorable prostate cancer","volume":"33","author":"Martinez","year":"2010","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.brachy.2025.10.013_bib0028","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijrobp.2011.08.002","article-title":"External-beam radiation therapy and high-dose rate brachytherapy combined with long-term androgen deprivation therapy in high and very high prostate cancer: preliminary data on clinical outcome","volume":"82","author":"Martinez-Monge","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2025.10.013_bib0029","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.radonc.2011.08.022","article-title":"Is single fraction 15 Gy the preferred high dose-rate brachytherapy boost dose for prostate cancer?","volume":"100","author":"Morton","year":"2011","journal-title":"Radiother Oncol"}],"container-title":["Brachytherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538472125003502?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538472125003502?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T07:41:18Z","timestamp":1781163678000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538472125003502"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S1538472125003502"],"URL":"https:\/\/doi.org\/10.1016\/j.brachy.2025.10.013","relation":{},"ISSN":["1538-4721"],"issn-type":[{"value":"1538-4721","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Feasibility of combining high-dose-rate prostate brachytherapy with dose intensification to the MRI dominant lesion followed by real-time adaptive MR-guided pelvic radiotherapy for high-risk prostate cancer","name":"articletitle","label":"Article Title"},{"value":"Brachytherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.brachy.2025.10.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Brachytherapy Society. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}